117 related articles for article (PubMed ID: 35834888)
1. Binding of Coxsackievirus A21 procapsids to immobilized glutathione depends on cell culture conditions during infection.
Swartz AR; Shieh Y; Gulasarian A; Olson JW; Rustandi RR
Virology; 2022 Aug; 573():167-175. PubMed ID: 35834888
[TBL] [Abstract][Full Text] [Related]
2. Glutathione affinity chromatography for the scalable purification of an oncolytic virus immunotherapy from microcarrier cell culture.
Swartz AR; Shieh Y; Gulasarian A; Curtis E; Hofmann CF; Baker JB; Templeton N; Olson JW
Front Bioeng Biotechnol; 2023; 11():1193454. PubMed ID: 37397964
[TBL] [Abstract][Full Text] [Related]
3. Reverse-Phase Ultra-Performance Chromatography Method for Oncolytic Coxsackievirus Viral Protein Separation and Empty to Full Capsid Quantification.
Deng JZ; Rustandi RR; Barbacci D; Swartz AR; Gulasarian A; Loughney JW
Hum Gene Ther; 2022 Jul; 33(13-14):765-775. PubMed ID: 35387488
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of Coxsackievirus A21 Viral Proteins in Mixtures of Empty and Full Capsids Using Capillary Western.
Gillespie PF; Rustandi RR; Swartz AR; Shang L; Raffaele J; Prout A; Cunningham N; Dawod M; Deng JZ; Wang S; Olson J; Shieh Y; Loughney JW
Hum Gene Ther; 2023 Jan; 34(1-2):68-77. PubMed ID: 36503264
[TBL] [Abstract][Full Text] [Related]
5. Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.
Newcombe NG; Johansson ES; Au G; Lindberg AM; Barry RD; Shafren DR
J Virol; 2004 Feb; 78(3):1431-9. PubMed ID: 14722298
[TBL] [Abstract][Full Text] [Related]
6. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
Johansson ES; Xing L; Cheng RH; Shafren DR
J Virol; 2004 Nov; 78(22):12603-12. PubMed ID: 15507647
[TBL] [Abstract][Full Text] [Related]
8. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
[TBL] [Abstract][Full Text] [Related]
9. Application of cation exchange chromatography in bind and elute and flowthrough mode for the purification of enteroviruses.
Konstantinidis S; Poplyk MR; Swartz AR; Rustandi RR; Thompson R; Wang SC
J Chromatogr A; 2022 Aug; 1676():463259. PubMed ID: 35759911
[TBL] [Abstract][Full Text] [Related]
10. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
Skelding KA; Barry RD; Shafren DR
Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
[TBL] [Abstract][Full Text] [Related]
11. Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.
Newcombe NG; Beagley LG; Christiansen D; Loveland BE; Johansson ES; Beagley KW; Barry RD; Shafren DR
J Virol; 2004 Nov; 78(22):12677-82. PubMed ID: 15507656
[TBL] [Abstract][Full Text] [Related]
12. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.
Au GG; Lincz LF; Enno A; Shafren DR
Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
Relph K; Annels N; Smith C; Kostalas M; Pandha H
Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
[TBL] [Abstract][Full Text] [Related]
15. Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21.
Skelding KA; Barry RD; Shafren DR
Breast Cancer Res Treat; 2009 Jan; 113(1):21-30. PubMed ID: 18256929
[TBL] [Abstract][Full Text] [Related]
16. The crystal structure of coxsackievirus A21 and its interaction with ICAM-1.
Xiao C; Bator-Kelly CM; Rieder E; Chipman PR; Craig A; Kuhn RJ; Wimmer E; Rossmann MG
Structure; 2005 Jul; 13(7):1019-33. PubMed ID: 16004874
[TBL] [Abstract][Full Text] [Related]
17. SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus.
Deng JZ; Rustandi RR; Swartz A; Shieh Y; Baker JB; Vlasak J; Wang S; Loughney JW
Mol Ther Oncolytics; 2022 Mar; 24():139-147. PubMed ID: 35024440
[TBL] [Abstract][Full Text] [Related]
18. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21.
Au GG; Lindberg AM; Barry RD; Shafren DR
Int J Oncol; 2005 Jun; 26(6):1471-6. PubMed ID: 15870858
[TBL] [Abstract][Full Text] [Related]
19. Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy.
Burnett WJ; Burnett DM; Parkman G; Ramstead A; Contreras N; Gravley W; Holmen SL; Williams MA; VanBrocklin MW
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503272
[TBL] [Abstract][Full Text] [Related]
20. Enterovirus IgM detection: specificity of mu-antibody-capture radioimmunoassays using virions and procapsids of Coxsackie B virus.
Frisk G; Nilsson E; Ehrnst A; Diderholm H
J Virol Methods; 1989; 24(1-2):191-202. PubMed ID: 2547815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
